当前位置:首页 - 行情中心 - 药易购(300937) - 财务分析 - 利润表

药易购

(300937)

  

流通市值:16.83亿  总市值:24.83亿
流通股本:6486.42万   总股本:9566.67万

利润表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、营业总收入1,113,920,5974,454,001,549.383,242,124,750.682,157,138,212.15
  营业收入1,113,920,5974,454,001,549.383,242,124,750.682,157,138,212.15
二、营业总成本1,099,524,353.694,421,142,447.43,215,835,561.022,136,963,938.03
  营业成本1,000,838,700.953,990,093,739.332,884,224,490.971,923,742,125.35
  税金及附加1,979,446.639,266,603.296,427,720.74,399,057.78
  销售费用73,889,959.27324,125,373.26257,750,651.18164,102,280.13
  管理费用18,376,677.4977,661,535.7652,007,950.2434,477,443.11
  研发费用2,518,249.7110,721,084.948,177,056.75,619,039.06
  财务费用1,921,319.649,274,110.827,247,691.234,623,992.6
  其中:利息费用1,870,410.63-6,245,323.064,519,758.88
  其中:利息收入366,111.74-2,605,554.651,435,151.29
三、其他经营收益
  加:公允价值变动收益-0--
  加:投资收益384,125.54-363,423.74937,267.79622,828.29
  汇兑收益-0--
  资产处置收益-2,770.27-9,311.77162,165.11121,117.81
  资产减值损失(新)-509,664.61-9,913,533.42-6,710,869.07-6,409,931.62
  信用减值损失(新)-11,717,520.22-15,766,038.85-18,085,506.5-12,660,591.75
  其他收益293,356.092,113,891.931,430,965.05591,811.03
四、营业利润2,843,769.848,920,686.134,023,212.042,439,507.88
  加:营业外收入53,285.75789,269.34224,117.9237,746.31
  减:营业外支出74,607.162,532,628.35662,435.98268,919.29
五、利润总额2,822,448.437,177,327.123,584,893.962,408,334.9
  减:所得税费用1,638,836.2823,633,056.9111,790,037.4711,473,266.97
六、净利润1,183,612.15-16,455,729.79-8,205,143.51-9,064,932.07
(一)按经营持续性分类
  持续经营净利润1,183,612.15-16,455,729.79-8,205,143.51-9,064,932.07
(二)按所有权归属分类
  归属于母公司股东的净利润-2,720,169.6-12,851,490.08-8,356,461.16-7,614,393.65
  少数股东损益3,903,781.75-3,604,239.71151,317.65-1,450,538.42
  扣除非经常损益后的净利润-3,084,111.65-14,302,015.24-10,152,605.74-8,323,130.54
七、每股收益
  (一)基本每股收益-0.03-0.13-0.09-0.08
  (二)稀释每股收益-0.03-0.13-0.09-0.08
九、综合收益总额1,183,612.15-16,455,729.79-8,205,143.51-9,064,932.07
  归属于母公司股东的综合收益总额-2,720,169.6-12,851,490.08-8,356,461.16-7,614,393.65
  归属于少数股东的综合收益总额3,903,781.75-3,604,239.71151,317.65-1,450,538.42
公告日期2026-04-292026-04-292025-10-242025-08-12
审计意见(境内)保留意见
TOP↑